Introduction Disability is linked to poor health outcomes and increased mortality, yet evidence on this relationship in sub-Saharan Africa is limited. This study investigated the association between ...

PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...

Higher intake of preservatives as food additives was associated with greater risk for cancer and breast cancer incidence.

The first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2. In 2024, the ...

Long-term survival data further support nivolumab plus ipilimumab as first-line standard of care for patients with inoperable liver cancer.

Higher-dose hydroxychloroquine in systemic lupus erythematosus is tied to lower risks for some cardiac conditions and no change in stroke, kidney, or cancer risks but higher eye risk in older adults.

In this study from ASCO GI 2026, researchers presented a 4-year follow-up of the phase 3 CheckMate 9DW trial of nivolumab plus ipilimumab in treatment-naïve HCC.

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, ...

Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

Large Norwegian registry data links birth size and maternal diabetes with higher multiple sclerosis risk, suggesting prenatal ...

Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...